Table 1.
Baseline characteristics before start of treatment
| Characteristic | Total (n=48) | PLA2R Antibody Negative (n=14) | PLA2R Antibody Positive (n=34) | P Value |
|---|---|---|---|---|
| Men (n) | 37 | 11 | 26 | 0.88 |
| Age (yr) | 55 (34–75) | 57 (38–75) | 54 (34–74) | 0.89 |
| Serum creatinine (mg/dl) | 1.60 (0.98–3.37) | 1.72 (1.24–3.37) | 1.54 (0.98–3.14) | 0.19 |
| Serum albumin (g/dl) | 2.6 (1.5–3.9) | 2.9 (1.5–3.9) | 2.4 (1.8–3.5) | 0.09 |
| Protein/creatinine ratio (g/g) | 10.1 (3.2–25.2) | 7.9 (5.1–23.5) | 10.5 (3.2–25.2) | 0.10 |
| SI | 0.34 (0.12–0.53) | 0.29 (0.12–0.51) | 0.35 (0.18–0.53) | 0.07 |
| eGFR (ml/min per 1.73 m2)a | 47 (21–96) | 41 (21–91) | 48 (21–96) | 0.50 |
| PLA2R antibody (U/ml) | 216 (1–16,260) | 9 (1–38) | 428 (41–16,260) | <0.01 |
| Severe nephrosis as reason for start treatment (n) | 2 | 0 | 2 | 0.35 |
| MMF (n) | 22 | 7 | 15 | 0.71 |
| Cyclophosphamide (n) | 26 | 7 | 19 | |
| Recurrent episode at presentation (n) | 9 | 4 | 5 | 0.26 |
| Previous immunosuppressive therapy (n) | 4/9 | 2/4 | 2/5 | 0.33 |
| Time from baseline to start treatment (mo) | 5 (1–26) | 4 (1–24) | 7 (1–26) | 0.40 |
| Follow-up duration (mo) | 52 (0–60) | 60 (0–60) | 47 (0–60) | 0.65 |
| Outcome | ||||
| Persistent remission | 21 | 7 | 14 | 0.58 |
| Relapse | 17 | 5 | 12 | 0.98 |
| Persistent proteinuria | 2 | 1 | 1 | 0.51 |
| Immunosuppressive therapy | 3 | 0 | 3 | 0.25 |
| Dead | 5 | 1 | 4 | 0.63 |
Unless otherwise noted, values are given as median and range. PLA2R, phospholipase A2 receptor; SI, selectivity index (ratio clearance IgG/clearance transferrin); MMF, mycophenolate mofetil.
a
eGFR was calculated with the Modification of Diet in Renal Disease-6 formula.